← Arbutus Biopharma Corp (ABUS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Arbutus Biopharma Corp (ABUS)
Pharmaceutical Preparations · market cap $967M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Arbutus Biopharma (NASDAQ: ABUS) is a Canadian biopharmaceutical company with 44 employees and a ~$901M market cap focused on hepatitis B and oncology, with expertise in liposomal drug delivery and RNA interference. Its pipeline includes two Phase 2 HBV assets (ARB-001467, AB-729) and one Phase 2 oncology asset (TKM-080301). With only $23.7M in cash and a runway of approximately 8.8 months, near-term financing risk is acute.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TKM-080301 | Phase 2 | Cancer |
| ARB-001467 | Phase 2 | Hepatitis B, Chronic |
| AB-729 | Phase 2 | Chronic Hepatitis b |
Price & technical context
3-month
-6.4%
6-month
+0.9%
12-month
+0.4%
52-wk range
$3.67–$5.22
vs 50-day MA
-5.6%
vs 200-day MA
+0.4%
Realized vol
45.6%
Max drawdown
-36.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABUS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.